Vitamin K Supplementation in Chronic Kidney Disease Patients: Where is the Evidence?

Area of Science:

• Nephrology
• Cardiology
• Nutritional Science

Background:

• Vascular calcification (VC) is common in chronic kidney disease (CKD), predicting cardiovascular (CV) mortality.
• Matrix Gla Protein (MGP), a VC inhibitor, needs vitamin K for activation.
• CKD patients often have poor vitamin K status and significant CV calcification.

Purpose of the Study:

• To review human studies on vitamin K supplementation in CKD patients.
• To explore vitamin K's role in mitigating VC progression and CV risk in CKD.
• To suggest future research directions in this field.

Main Methods:

• Focus on interventional human studies.
• Analysis of vitamin K supplementation effects on VC and MGP activity.
• Review of epidemiological data linking vitamin K status to VC and CV outcomes.

Main Results:

• Epidemiological data link vitamin K depletion to VC progression and adverse CV outcomes.
• Vitamin K supplementation (especially menaquinone 7) may reduce inactive MGP.
• Potential for retarding or reversing VC in early and advanced CKD.

Conclusions:

• Vitamin K supplementation is a promising strategy for managing VC in CKD patients.
• Further interventional studies are needed to confirm efficacy and optimal protocols.
• Addressing vitamin K deficiency is crucial for cardiovascular health in CKD.